Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    51,201.89
    -746.54 (-1.44%)
     

  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Sanofi to run consultations over restart of hydroxychloroquine trials

Reuters
·1-min read
FILE PHOTO: Sanofi logo is seen in Paris

PARIS (Reuters) - Sanofi said on Wednesday it would review available information and run consultations before deciding whether to enroll patients again for its COVID-19-related hydroxychloroquine trials.

The French drugmaker said on May 29 it had stopped recruiting new COVID-19 subjects for two clinical trials on hydroxychloroquine until concerns about safety are cleared up following a decision by the World Health Organization to pause a large trial.

The WHO said earlier in the day the trial would resume.

"We will review available information and run consultations in the coming days to reassess our position," a spokesman with Sanofi said.

(Reporting by Matthias Blamont; Editing by Benoit Van Overstraeten)